Literature DB >> 27716752

Diabetes: Steno-2 - a small study with a big heart.

Harpreet Bajaj1, Bernard Zinman2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27716752     DOI： 10.1038/nrendo.2016.172

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up.

Authors: 
Journal:  Diabetes Care       Date:  2016-02-09       Impact factor: 19.112

2.  Intensive lifestyle intervention in type 2 diabetes.

Authors:  Rena R Wing; David Reboussin; Cora E Lewis
Journal:  N Engl J Med       Date:  2013-12-12       Impact factor: 91.245

3.  Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.

Authors:  Rodney A Hayward; Peter D Reaven; Wyndy L Wiitala; Gideon D Bahn; Domenic J Reda; Ling Ge; Madeline McCarren; William C Duckworth; Nicholas V Emanuele
Journal:  N Engl J Med       Date:  2015-06-04       Impact factor: 91.245

4.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

5.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

6.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

7.  Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes.

Authors: 
Journal:  Diabetes Care       Date:  2016-01-28       Impact factor: 19.112

8.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

9.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

Authors:  Sophia Zoungas; John Chalmers; Bruce Neal; Laurent Billot; Qiang Li; Yoichiro Hirakawa; Hisatomi Arima; Helen Monaghan; Rohina Joshi; Stephen Colagiuri; Mark E Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Liu Lisheng; Giuseppe Mancia; Michel Marre; David R Matthews; Carl E Mogensen; Vlado Perkovic; Neil Poulter; Anthony Rodgers; Bryan Williams; Stephen MacMahon; Anushka Patel; Mark Woodward
Journal:  N Engl J Med       Date:  2014-09-19       Impact factor: 91.245

10.  Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.

Authors:  Peter Gæde; Jens Oellgaard; Bendix Carstensen; Peter Rossing; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  Diabetologia       Date:  2016-08-16       Impact factor: 10.122
  10 in total
  3 in total

1.  Metabolic Stress and Cardiovascular Disease in Diabetes Mellitus: The Role of Protein O-GlcNAc Modification.

Authors:  Yabing Chen; Xinyang Zhao; Hui Wu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-29       Impact factor: 8.311

2.  Type 2 diabetes in general practice in Norway 2005-2014: moderate improvements in risk factor control but still major gaps in complication screening.

Authors:  Åsne Bakke; John G Cooper; Geir Thue; Svein Skeie; Siri Carlsen; Ingvild Dalen; Karianne Fjeld Løvaas; Tone Vonheim Madsen; Ellen Renate Oord; Tore Julsrud Berg; Tor Claudi; Anh Thi Tran; Bjørn Gjelsvik; Anne Karen Jenum; Sverre Sandberg
Journal:  BMJ Open Diabetes Res Care       Date:  2017-11-08

3.  Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.

Authors:  Silvio E Inzucchi; Kamlesh Khunti; David H Fitchett; Christoph Wanner; Michaela Mattheus; Jyothis T George; Anne Pernille Ofstad; Bernard Zinman
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.